Cargando…

Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

INTRODUCTION: Despite currently available treatments for adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL), survival outcomes remain poor, highlighting the need for new therapeutic strategies. This study estimates the cost-effectiveness of KTE-X19 to treat adults with R/R ALL fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Bijal D., Smith, Nathaniel J., Feng, Chaoling, Jeyakumar, Sushanth, Castaigne, Jean-Gabriel, Faghmous, Imi, Masouleh, Behzad Kharabi, Malone, Daniel C., Bishop, Michael R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309154/ https://www.ncbi.nlm.nih.gov/pubmed/35727476 http://dx.doi.org/10.1007/s12325-022-02201-6

Ejemplares similares

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
por: Shah, Bijal D., et al.
Publicado: (2022)

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Wayne, Alan S., et al.
Publicado: (2022)

KTeV startup and status
por: Kessler, R S
Publicado: (1996)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

The KTeV hardware cluster counter
por: Bown, C, et al.
Publicado: (1995)

The KTeV CsI calorimeter
por: Roodman, A
Publicado: (1996)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018)

P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2
por: Wang, M. L., et al.
Publicado: (2022)

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
por: Jain, Michael D, et al.
Publicado: (2018)

Drugging the unfolded protein response in acute leukemias
por: Kharabi Masouleh, Behzad, et al.
Publicado: (2015)

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2019)

Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Williams, Sherry, et al.
Publicado: (2018)

First result from KTeV on epsilon epsilon
por: Winstein, Bruce D
Publicado: (1999)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
por: Wang, Michael, et al.
Publicado: (2023)

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
por: Shah, Bijal D, et al.
Publicado: (2023)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2015)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
por: Zhao, Junmei, et al.
Publicado: (2015)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
por: Uy, Natalie, et al.
Publicado: (2018)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
por: Bertamini, Luca, et al.
Publicado: (2018)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Development and performance of the KTeV transition radiation detector system
por: Solomey, Nickolas
Publicado: (1998)

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
por: Gökbuget, N, et al.
Publicado: (2016)

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
por: Hathaway, Lindsey, et al.
Publicado: (2018)

An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia
por: Ma, Jun, et al.
Publicado: (2018)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
por: Queudeville, Manon, et al.
Publicado: (2017)

Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
por: Topp, Max S., et al.
Publicado: (2020)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia
por: Graiqevci-Uka, Violeta, et al.
Publicado: (2022)

Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia
por: Wilhelm, Thomas, et al.
Publicado: (2017)

Deregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph(+) leukemia
por: Vieri, Margherita, et al.
Publicado: (2016)

New results in kaon physics from NA48 and KTeV
por: Wanke, Rainer
Publicado: (2003)

XBP1 promotes NRAS(G12D) pre‐B acute lymphoblastic leukaemia through IL‐7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS
por: Salimi, Azam, et al.
Publicado: (2023)

Testicular relapse of acute lymphoblastic leukemia()
por: Carolan, Alexandra, et al.
Publicado: (2023)

Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
por: Davis, Tyler, et al.
Publicado: (2013)

Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia'
por: Tong, W H
Publicado: (2016)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8sbsa6ntb2oi707f0c5evh0kon